
Ozempic and Mounjaro are both once-weekly injections, but they contain different medicines and are licensed for different things in the UK. Ozempic contains semaglutide and is licensed for type 2 diabetes. Mounjaro contains tirzepatide and is licensed for both type 2 diabetes and weight management. Mounjaro acts on two gut hormones rather than one and, in trials, has generally led to more weight loss. For weight management, the semaglutide brand is Wegovy, so the like-for-like weight loss comparison is really Mounjaro vs Wegovy.
Ozempic, Wegovy and Mounjaro at a glance
| Ozempic | Wegovy | Mounjaro | |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Licensed in the UK for | Type 2 diabetes | Weight management | Type 2 diabetes and weight management |
| Hormones it acts on | GLP-1 | GLP-1 | GIP and GLP-1 |
| How it's taken | Injection once a week | Injection once a week | Injection once a week |
| Dose steps | 0.25mg, 0.5mg, then 1mg or 2mg if needed | 0.25mg rising every 4 weeks to 2.4mg (7.2mg for some adults) | 2.5mg rising in 2.5mg steps to a maximum of 15mg |
| Average weight loss in the main weight trials | Not licensed for weight loss, so not included here | About 15% at 2.4mg over 68 weeks | About 15% to 21%, depending on dose, over 72 weeks |
How they work
Semaglutide copies GLP-1, a hormone your gut releases after eating. It helps your body release insulin when blood sugar rises, slows down how quickly your stomach empties and acts on the brain's appetite centres, so you feel full sooner and less hungry.
Tirzepatide copies GLP-1 too, but it also copies a second gut hormone, GIP. Acting on both hormones is thought to be why it has led to more weight loss in trials, although the full reasons aren't yet understood.
Weight loss compared
The figures most often quoted come from different trials, so it's worth knowing where each one comes from:
- Wegovy (semaglutide 2.4mg): in the STEP 1 trial, adults lost about 15% of their body weight on average over 68 weeks. The "15%" figure sometimes attributed to Ozempic actually comes from this Wegovy trial; Ozempic's diabetes doses are lower.
- Mounjaro (tirzepatide): in the SURMOUNT-1 trial, adults lost about 15% of their body weight on average at 5mg and about 21% at 15mg over 72 weeks.
- Head to head: the SURMOUNT-5 trial, published in 2025, compared the two directly in adults with obesity but without diabetes. After 72 weeks, average weight loss was about 20% with tirzepatide and about 14% with semaglutide.
These are averages from trials in which people also had diet and activity support. Some people lose much more and some much less, and weight usually returns to some degree if treatment stops.
Doses
Mounjaro starts at 2.5mg once a week for 4 weeks, then usually goes up in 2.5mg steps every 4 weeks, to a maximum of 15mg. Not everyone needs the higher doses.
Ozempic starts at 0.25mg once a week for 4 weeks, then 0.5mg, and can go up to 1mg or 2mg for blood sugar control. Wegovy goes up every 4 weeks through 0.25mg, 0.5mg, 1mg and 1.7mg to the usual maintenance dose of 2.4mg.
Your prescriber decides each step with you, based on how you respond and how well you tolerate it.
Side effects and safety
Both medicines have similar side effects. The most common are feeling sick, diarrhoea, constipation, vomiting, indigestion and tummy pain, which are usually worst after starting or increasing a dose. Eating smaller meals and stopping when you feel full can help. If you're being sick or have diarrhoea, drink plenty of fluids, as dehydration can affect your kidneys.
Get urgent medical help if you have:
- severe tummy pain that doesn't go away, sometimes spreading to your back (a possible sign of pancreatitis)
- pain in the upper right of your tummy, a high temperature, or yellowing of your skin or eyes (possible gallbladder problems)
- signs of a serious allergic reaction, such as swelling of the face or throat, or difficulty breathing
If you have diabetes and also take insulin or a sulfonylurea, your doses may need adjusting to avoid low blood sugar.
Contraception and pregnancy: Mounjaro can make the contraceptive pill less effective. Use condoms as well for 4 weeks after starting and for 4 weeks after each dose increase, or switch to a non-pill method such as the coil or implant. Neither medicine should be used during pregnancy, while trying to get pregnant or while breastfeeding. Stop semaglutide at least 2 months, and tirzepatide at least 1 month, before trying for a baby. The MHRA's guide to GLP-1 medicines explains this in more detail.
Who can use them?
Wegovy and Mounjaro can be prescribed for weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or type 2 diabetes. They're used alongside a reduced-calorie diet and more physical activity, not instead of them. UK pharmacies must check your weight before supplying them. Ozempic is licensed for adults with type 2 diabetes.
They aren't suitable for everyone, including people who have had pancreatitis or have type 1 diabetes. Read more about Mounjaro (tirzepatide) and Ozempic and Wegovy (semaglutide), including how our prescribers decide whether a medicine is suitable, or compare all our weight loss treatments.
Ozempic vs Mounjaro FAQs
Is Mounjaro stronger than Ozempic?
Tirzepatide (Mounjaro) has led to more weight loss than semaglutide in trials, including a 2025 head-to-head study. But they're different medicines licensed for different uses, and the right one depends on your health, what it's being used for and how well you tolerate it.
Can I switch from Ozempic or Wegovy to Mounjaro?
Yes, but only with your prescriber's advice, and you never use both together. The prescriber chooses your Mounjaro starting dose, and you usually take your first dose on the day your next semaglutide injection would have been due.
Does Mounjaro affect the pill?
It can make the contraceptive pill less effective, particularly for 4 weeks after starting and for 4 weeks after each dose increase. Use condoms as well during those times, or switch to a non-pill method such as the coil or implant.
Is Mounjaro licensed for weight loss in the UK?
Yes. Mounjaro is licensed for weight management in adults with a BMI of 30 or more, or 27 or more with a weight-related health condition, alongside a reduced-calorie diet and more physical activity. It's also licensed for type 2 diabetes.
Which has fewer side effects?
Their side effects are similar: mainly feeling sick, diarrhoea, constipation and vomiting, usually worst when you start or increase the dose. In the head-to-head trial, slightly fewer people stopped tirzepatide than semaglutide because of stomach side effects, but everyone responds differently.
Further reading
Sources:
- NHS: Tirzepatide
- NHS: Semaglutide
- NICE TA1026: Tirzepatide for managing overweight and obesity
- NICE TA875: Semaglutide for managing overweight and obesity
- MHRA: GLP-1 medicines for weight loss and diabetes
This article was originally written for MedsRus by Pharmacy Mentor.
